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Abstract
Trace amine-associated receptors (TAAR) are rhodopsin-like G-protein-coupled receptors (GPCR). TAAR are involved in
modulation of neuronal, cardiac and vascular functions and they are potentially linked with neurological disorders like
schizophrenia and Parkinson’s disease. Subtype TAAR1, the best characterized TAAR so far, is promiscuous for a wide set of
ligands and is activated by trace amines tyramine (TYR), phenylethylamine (PEA), octopamine (OA), but also by
thyronamines, dopamine, and psycho-active drugs. Unfortunately, effects of trace amines on signaling of the two
homologous b-adrenergic receptors 1 (ADRB1) and 2 (ADRB2) have not been clarified yet in detail. We, therefore, tested
TAAR1 agonists TYR, PEA and OA regarding their effects on ADRB1/2 signaling by co-stimulation studies. Surprisingly, trace
amines TYR and PEA are partial allosteric antagonists at ADRB1/2, whereas OA is a partial orthosteric ADRB2-antagonist and
ADRB1-agonist. To specify molecular reasons for TAAR1 ligand promiscuity and for observed differences in signaling effects
on particular aminergic receptors we compared TAAR, tyramine (TAR) octopamine (OAR), ADRB1/2 and dopamine receptors
at the structural level. We found especially for TAAR1 that the remarkable ligand promiscuity is likely based on high amino
acid similarity in the ligand-binding region compared with further aminergic receptors. On the other hand few TAAR specific
properties in the ligand-binding site might determine differences in ligand-induced effects compared to ADRB1/2. Taken
together, this study points to molecular details of TAAR1-ligand promiscuity and identified specific trace amines as allosteric
or orthosteric ligands of particular b-adrenergic receptor subtypes.
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Introduction
The group of trace amine-associated receptors (TAAR) [1]
belongs to the rhodopsin-like family of G protein-coupled
receptors (GPCRs) and is of importance for several physiological
aspects such as proper cardiac and vascular functions (reviews
[2,3,4,5]). It has also been proposed that TAAR are involved as
neuromodulators in brain [2,6]. In accordance, TAAR are
postulated to be linked with neurological disorders like bipolar
disease [7,8], schizophrenia [9,10], depression and Parkinson’s
disease [11,12]. In consequence, TAAR are potential new
important therapeutic targets for several pathological situations
[13,14]. The first human member of this receptor group (TAAR5)
was identified in 1998 [15,16] and the term TAAR was introduced
when TAAR1, TAAR8 and TAAR9 were discovered [17]. Three
out of the nine hTAAR members are pseudogenes [18]. TAAR1 is
activated by trace amines [6] such as tyramine (TYR), b-
phenylethylamine (PEA) or octopamine (OA) [17,19] and signals
via the Gs protein/adenylyl cyclase system. In addition, it was
reported that a thyroid hormone derivative, 3-thyronamine
(T1AM) [20,21,22,23,24,25,26,27,28,29] activates TAAR1. Re-
markable differences in efficacies of T1AM between hTAAR1 and
rodent Taar1 were observed [30]. In addition, ligands of the
dopamine-, serotonine-, histamine-, or adrenergic receptors are
able to induce TAAR1 mediated signaling [17,19,31,32].
Surprisingly, antagonists of the serotonin receptor like cyprohep-
tadine as well as antagonists of adrenergic receptors like
phentolamine are Taar1 agonists [19]. Besides trace amines and
biogenic amines also volatile amines activate human TAAR1 and
murine Taar 3, 5, and 7 [33], characterizing these TAAR
additionally as odorant receptors [34,35,36]. Finally, TAAR1
responds to psycho-active drugs [19,37]. This points, altogether, to
an enormous TAAR1 ligand-binding promiscuity that might
reflect also the evolutionary link between TAAR and homologous
vertebrate aminergic receptors [2,17,18,38,39,40] or invertebrate
tyramine receptors (TAR) and octopamine receptors (OAR).
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endogenous neuromodulators of classical monoamine neurotrans-
mitters [41,42]. In contrast, in the tyramine/octopamine system in
invertebrates, the homologue to the mammalian adrenergic system
[43,44], trace amines are acting as direct neurotransmitters. Trace
amines and their invertebrate receptors are involved in regulation
of metabolism and of sensory and behavioral functions [44].
Several tyramine and octopamine receptors were identified in
invertebrates like insects [44,45,46,47] or mollusks [48]. Of note,
the overlap in homologous receptor-ligand systems has also
unexpected consequences. For example TAR and OAR are
targets for insecticid development [44] and these substances could
potentially affect TAAR or other aminergic receptors. In reverse,
b-blockers have an endocrine-disrupting potential on organisms
with TAR and OAR expression [49]. It is well known that
particular ligands interact with several different aminergic
receptors or modulate different physiological systems. Octopamine
has been shown previously to be an agonist at the a-adrenergic
receptor [50,51] and the b3-adrenergic receptor [52]. Substance
PEA may act as an a-adrenergic receptor antagonist [53]. The
OAR of Lymnaea stagnalis was found to be activated by a2-
adrenergic receptor ligands, which leads in case of OAR to
activation of both Gs- and Gq-mediated pathways [48]. Further-
more, it can be postulated from several studies that TAAR1
function might be related with the dopamine-2 receptor
[54,55,56,57,58] as well as with the serotonin receptor 5-HT(1A)
[59]. Recently published evidence points to a physiological role for
T1AM as an endogenous adrenergic-blocking neuromodulator in
the central noradrenergic system [22]. In conclusion, a wide
spectrum of potential ligand-aminergic receptor combinations or
modulation of different physiological systems by specific ligands
has been recognized. But, reflecting possible cross-combinations of
the huge number of potential interaction partners this complex
system is only recognized fragmentarily.
Herein we tested particular trace amines acting as agonists on
hTAAR1 regarding their direct effects on hADRB1 and hADRB2
signaling. We found allosteric and orthosteric antagonistic effects
of particular trace amines on ADRB1 and ADRB2. Octopamine
induced different signaling effects on ADRB1 and ADRB2. Based
on these findings we investigated the structural basis of TAAR
ligand-promiscuity by comparative studies to other aminergic
receptors and found similarities and differences between aminergic
receptors which help to explain differential modification of
signaling induced by trace amines.
Results
Different effects of trace amines at hTAAR1 and human
b-adrenergic receptors
Ligands PEA, TYR and OA (figure 1) activate hTAAR1 [17,19]
with subsequent stimulation of adenylyl cyclase and cAMP
formation (figure 2, supplemental figure S1). Of note, hTAAR1
exhibits a high level of basal constitutive (ligand independent)
signaling activity (73614 nM cAMP) compared to mock trans-
fected cells (figure 2). This hTAAR1 characteristic is in accordance
to the reported effects of inverse agonists effecting ligand
independent signaling activity of TAAR1 [60,61].
For describing the functional effects of PEA, TYR and OA we
use the following terms: allosteric antagonist if a non-competitive
effect on ISOP is observed and orthosteric antagonist if a
competitive effect occurs. The most potent agonist tested was
PEA (Emax=403654 nM), followed by TYR (Emax=2196
67 nM) and OA (Emax=172642 nM) (figure 2 and supplemental
figure S1).
Isoprenaline (ISOP) is a full agonist to b-adrenergic receptors
and was also reported as an agonist to TAAR1 [19]. We
functionally tested the effects of particular trace amines at the
human ADRB1 and ADRB2 (figure 3). Therefore, HEK293 cells
(ATCC-LGC, Wesel, Germany) were transiently transfected with
hADRB1 or hADRB2 and incubated with TYR, PEA or OA
alone or in presence of ISOP. For competition experiments we
prestimulated ADRB1 and ADRB2 with each trace amine TYR,
PEA and OA in concentrations ranging from 6.7 nM to 6700 nM
[17,19]. Then, ISOP in concentrations from 1 nM up to
10000 nM was added and cAMP accumulation was measured.
Controls were stimulated with each trace amine and ISOP alone,
respectively.
As shown in figure 3A-B, TYR acted as an allosteric antagonist
at both, ADRB1 and ADRB2, by decreasing the Emax values to
30% and 60% of the wild type receptor, respectively, when
compared to ISOP alone. A small increase of ADRB2 signaling at
highest TYR concentrations was not significant. The concentra-
tion-response curves revealed no shift in the EC50 value (figure 3A,
table 1) indicating a non-competitive allosteric effect of TYR on
ISOP-stimulated ADRB1 and ADRB2. Similarly, PEA non-
competitively antagonized signaling of both ADRB1 and ADRB2
(figure 3C, D).
In contrast, OA acted as an agonist to hADRB1 (figure 3E),
but with lower potency (EC50 31296461 nM) than ISOP
(EC50=61610 nM) (table 1). OA together with ISOP showed
slightly differences in their EC50 values. Nevertheless, there were
no changes in Emax values (table 1, figure 3E) detectable.
Interestingly, OA did not activate ADRB2 but acted as an
orthosteric antagonist by inhibiting ISOP activation competitively
(figure 3F).
Structural similarities and differences between hTAAR
and homologous aminergic receptors
Our knowledge concerning ligand binding at b-adrenergic
receptors and other members of the rhodopsin-like GPCR family
has been dramatically increased since crystal structures of ADRB1,
ADRB2, and dopamine-3 receptor (DRD3) in complex with
antagonists or agonists recently became available [62,63,64,65].
These crystal structures provide molecular details of intermolec-
ular interaction between receptor proteins and small molecules
with respect to the location of ligands, their orientation and
intermolecular interaction partners (figure 4A–C). TAAR, OAR/
TAR of invertebrates and classical aminergic receptors show high
amino acid sequence identities (supplemental material figure S2).
To compare hTAAR with aminergic receptors we analyzed
determinants of the b2-adrenergic ligand-binding region (figure 4
and figure 5) and designed human TAAR homology models based
on the b2-adrenergic receptor conformation (figure 6A, supple-
mental material figure S3). This is reasonable because TAAR1
shows highest sequence similarity to ADRB1 (,35%) and ADRB2
(,39%) and TAAR1 is activated by adrenergic receptor agonists
such as isoprenaline [19,30].
Structural properties and specificities of TAAR. TAAR
are structurally constituted by an extracellular N-terminal tail
(Ntt), seven transmembrane helices (TMH1-7), three extracellular
loops (ECL1-3), three intracellular loops (ICL1-3) and an
intracellular C-terminal part (Ctt). TAAR share specific highly
conserved amino acids in the TMH with all rhodopsin-like GPCR
[66]. One of the main structural difference between GPCR is the
conformation and spatial localization of ECL2 [67]. While in
rhodopsin a b-sheet like fold is observable, crystal structures of
adrenergic receptors show a helical ECL2 conformation. We
suggest based on the sequence alignment that ECL2 of TAAR is in
Trace Amines as Adrenergic Receptor Ligands
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cysteine-bridges: i. the highly conserved cysteine bridge between
ECL2 and TMH3, and ii. between ECL2 and ECL1 (figure 6A).
Disulphide-bridged extracellular loops 1 and 2 are also observable
in the crystal structure of adenosine-2A receptor (pdb entry code
3EML [68]) and this interaction is of structural and functional
relevance [69,70].
Defining the ligand binding region of aminergic
receptors. As shown in figure 4 the ligand binding region of
adrenergic receptors is located between the extracellular ends of
the transmembrane helices. This pocket-like crevice is covered by
specific amino acids [71] which are predestinated for interaction
with ligands in different particular modes [72]. For comparison of
amino acids (figure 5) which are potentially important for ligand
binding at different aminergic receptors we depicted those amino
acids of ADRB2 that are determinants of this spatial region
(figure 4, figure 6A). We found that most of the ligand binding-
sensitive side chains in aminergic receptors (e.g. positions 2.57,
3.32, 6.48, 6.51, 7.53) are also conserved in TAAR. This is also
reflected by our homology model of hTAAR1 compared with the
crystal structure of ADRB1 (figure 6A). hTAAR1 is, in contrast to
other TAAR, characterized by six additional residues which are
similar to the binding pocket of b-adrenergic receptors (figure 5),
including specific amino acids at TMH5 positions 5.42 and 5.46.
Their side chains are known to be important for signaling and
ligand specific signaling effects [73,74]. These two residues are also
conserved in DRD3 and TAR/OAR. However, the observ-
able high sequence similarity might explain TAAR1 ligand
promiscuity. In contrast, also significant differences between
ADRB1/ADRB2 compared to hTAAR1 are observable by
comparison of amino acids in the ligand binding region.
Especially the asparagines at positions 6.55 (TMH6) and 7.39
(TMH7) are known to be important for ligand binding at
Figure 1. Molecular structures of ADRB1/2 and TAAR1 ligands. The trace amines TYR, PEA and OA are agonists of TAAR1. In contrast, TYR and
PEA are antagonists on ADRB1/2, most likely due to less hydroxyl groups compared OA or already known agonistic beta-adrenergic ligands (grey
circles). OA has an additional hydroxyl group (grey circle), but yet a hydroxyl group less (dashed grey circle) compared to full ADRB1/2 agonists
isoprenaline, adrenaline and noradrenaline.
doi:10.1371/journal.pone.0027073.g001
Figure 2. Functional characterization of hTAAR1 interacting
with different trace amines. HEK293 cells transiently transfected
with hTAAR1 and were incubated for 45 minutes with 10 mM of PEA,
OA and TYR. Basal signaling activity as well as activation of the Gs
protein/adenylyl cyclase pathway was determined by AlphaScreen
technology. Data represent mean 6 SEM of cAMP accumulation after
stimulation from 4–5 independent experiments performed in triplicates.
TAAR1 showed an elevated ligand independent basal activity. PEA was
the most potent agonist (p,0.01), followed by TYR (p,0.05) and OA
(p,0.05). Data were analyzed using a paired one-tailed t-test.
doi:10.1371/journal.pone.0027073.g002
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e27073Figure 3. Characterization of hADRB1 and hADRB2 after trace amine challenge. HEK293 cells were transiently transfected with hADRB1
and hADRB2, respectively. Cells were pre-incubated with increasing concentrations of the trace amines TYR, PEA or OA (6.7 nM to 6700 nM) for 15
minutes. For competition studies ISOP with increasing concentrations (10000 nM to 1 nM) was added and incubated for additional 30 minutes. As
controls hADRB1 and hADRB2 were incubated with each substance alone with the same concentration for 45 minutes. Three to four independent
experiments measured in duplex or tripletts mean 6 SEM are depicted here. Fold over mock was calculated and expressed as percentage of ISOP
stimulation (100%). Maximal values were statistically analyzed using paired one-tail t-test compared to ISOP maximal stimulation. A-B) hADRB1 and
hADRB2 were stimulated with ISOP and TYR alone and with both substances simultaneously. TYR shows no agonistic effect on hADRB1 (p,0.05) and
hADRB2 (p,0.01), but acts as an allosteric antagonist on hADRB1/2, indicated by a decreased maximum of stimulation (p,0.05) with comparable
EC50 values. C-D) PEA shows no agonistic effects on both hADRB1 (p,0.01) and hADRB2 (p,0.05) but leads to a decreased maximum of stimulation
by ISOP when pre-incubated with PEA (p,0.05). The EC50 value is similar to stimulation with ISOP alone. E) OA acts as an agonist on hADRB1 but with
a decreased efficacy. Simultaneous incubation with ISOP and OA reveals no antagonistic effect of OA on hADRB1 (table 1). F) OA is an orthosteric
antagonist on hADRB2, indicated by a right shift of the EC50 value. OA however showed no agonistic effect on hADRB2 (p,0.05).
doi:10.1371/journal.pone.0027073.g003
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OAR and TAR.
Comparison of hTAAR subtypes. On note, there are also
molecular differences in the ligand-binding region between
hTAAR1 and further hTAAR group members (figure 5).
Mapping amino acids that are different between TAAR1 and
other hTAAR subtypes to the structural homology models of all
hTAAR members a particular spatial region between TMH3,
TMH5 and TMH6 is most diverse in biophysical properties
(supplemental material figure S3). Such region with divergent
properties might cause differences of TAAR subtype-ligand
sensitivity or induced effects of ligands [3,18,75,76]. Despite
these differences between hTAAR a specific set of identical amino
acids in the ligand binding region of TAAR is constituted by
residues S2.61, R2.64 (TMH2); H3.28, S/C3.36 (TMH3); F/
Y4.56 (TMH4); D6.58 (TMH6); and D7.36 (TMH7). These
amino acids with few exceptions are not found in DRD3,
ADRB1/2 or TAR and OAR. In conclusion, those residues and
spatial potential ligand-binding region between TMH2, TMH3,
TMH6 and TMH7 (supplemental material figure S3) are
predestinated to interact with so far unknown TAAR-selective
ligands.
Discussion
A diverse spectrum of ligands including trace amines interacts
with aminergic receptors and modulates different physiological
functions. We show here, that the ligand-binding region of
TAAR1 is characterized by high similarity to other aminergic
GPCR like ADRB1, DRD3 or TAR/OAR. Trace amines such as
PEA, TYR and OA (figure 1) can activate hTAAR1 via the Gs
protein/adenylyl cyclase pathway. Human TAAR1 possesses a
ligand independent basal activity and PEA is the most potent
agonist, followed by TYR and OA (figure 2, supplemental material
figure S1). In accordance, a previous experimental study
demonstrated that ligands on hTAAR1 interact with typical
binding-motifs of aminergic receptors [77]. Of note, also for non-
human TAAR3 and TAAR4 subtypes (e.g. TAAR orthologs from
rat and mouse) ligand promiscuity was reported, but for different
ligands compared to hTAAR1. TAAR3 and TAAR4 are
pseudogenes in humans [18].
We here tested TAAR1 agonists TYR, PEA and OA regarding
their effects on ADRB1/2 signaling. We found that TYR and
PEA are allosteric antagonists at both tested b-adrenergic
receptors, whereas OA was a weak orthosteric ADRB2-
antagonist and a weak ADRB1-agonist. This finding revealed
trace amines TYR, PEA and OA as potential endogenous ligands
for ADRB1 and ADRB2, but primarily as partial antagonists.
Secondly, despite high similarities between the hTAAR1 and
ADRB1/2, allosteric modification of isoprenaline induced
activation of ADRB1 and ADRB2 by TYR and PEA points to
differences in details of ligand binding and action. The ligands
PEA and TYR are distinguished from OA and ISOP by a lower
number of hydroxyl-groups at the aliphatic chain (figure 1). The
additional hydroxyl-group of OA and ISOP interacts via H-bond
with an asparagine (position 7.39) at TMH7 as observed in the
ADRB1 crystal structure (figure 6B). Of special note, amino acids
side chains at this position were already identified being involved
in determination of binding properties and selectivity of ligands
on rat and mouse TAAR1 [78]. This anchor-contact towards
TMH7 (H-bond to 7.39) can not be assumed for TYR and PEA
due to a lack of this specific hydroxyl-group (figure 1). In
consequence, differences in the orientation of TYR and PEA at
ADRB1/2 compared to observed localization of ISOP in the
orthosteric binding pocket of ADRB1 between TMH3, TMH5,
TMH6, and TMH7 are likely. In conclusion, allosteric effects of
PEA or TYR for co-stimulation with ISOP can be explained by a
different orientation of both ligand subtypes in the ligand-binding
region. The ADRB1 crystal structure co-crystallized with ISOP
reveals a spatial region for potential binding of allosteric
antagonists TYR and PEA close to the binding site of agonist
ISOP (figure 6B). Based on our findings we assume a second
binding site at ADRB1 and ADRB2 which can be occupied by
small molecule antagonists.
OA with a hydroxyl-group at the phenyl ring and at the
hydrophilic side chain (figure 1) is able to interact with N7.39 at
TMH7 like ISOP at ADRB1 and is therefore likely localized
similarly to other adrenergic ligands and induces orthosteric
effects. Studies on invertebrate adrenergic receptor-like trace
amine receptors point indeed to similar or identical details of
octopamine/receptor interactions compared to adrenergic recep-
tors. Huang and co-workers [79] provided evidence for partici-
pation of serine D3.32 (TMH3) and S5.42 (TMH5) for activation
of octopamine receptor by OA. However, the different effects of
OA at ADRB1 (agonistic) versus ADRB2 (neutral in the basal state
and antagonistic for ISOP treatment) are likely related to
peculiarity of interaction between the hydroxyl-group at the
phenylic ring system with hydrophilic residues at TMH5 (positions
5.42, 5.46) as suggested for other ligands [80]. Alternatively,
differences to other adrenergic-ligands might be caused by
changed interactions to the asparagine at position 6.55 which is
observable at ADRB1 complexed with ISOP (figure 6B). Of note,
an aromatic residue at TMH6 at position Y6.55 was found as a
molecular switch for G-protein preference of OAR [81].










PEA+ISOP 41698 7 68
OA+ISOP 210674 2706104




TYR+ISOP 20631 6 7 635
PEA+ISOP 44691 6 2 652
OA+ISOP 249670 443650
hTAAR1 TYR 15406251 219667
PEA 260616 403654
OA 417061470 172642
EC50 values were calculated using GraphPadPrism from concentration response
curves of measured cAMP accumulation. Displayed is the mean 6 SEM from
n$3 independent experiments. Emax values mean 6 SEM from n$3
independent experiments were calculated from fold over mock data. ‘‘–‘‘not
determinable with sufficient accuracy, ‘‘*’’ not determinable due to extremely
low stimulation.
doi:10.1371/journal.pone.0027073.t001
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comparison we showed that the general ligand binding region of
hTAARs is characterized by high amino acid conservation
specifically in a crevice between the interfaces of TMH 2, 3, 6
and 7 (figure 5 and supplemental figure S3). This region is termed
minor pocket [82] as part of the entire ligand binding region known
for family A GPCRs [72]) and is not occupied by isoprenaline in
the ADRB1 crystal structure (figure 6B), nor by carazolol in
ADRB2 (figure 4B). Therefore we here hypothesize a preference of
this pocket for a shared endogenous and also so far unknown
TAAR ligand(s). In addition, our comparative studies also revealed
that hTAAR1 is significantly different from all other hTAAR
group members in the general ligand binding region. This likely
would explain non-responsiveness of other hTAARs to particular
ligands of TAAR1.
Taken together, we here present molecular details causing
TAAR1 ligand promiscuity. We also found different effects of trace
amines at hTAAR1 versus hADRB1 and hADRB2 which can be
explained by complementary properties at ligands and receptors.
Particular TAAR1 agonists are inhibitors of b-adrenergic receptor
subtypes. These differences in ligand-induced effects are caused by
specific properties of TAAR1 compared to ADRB1 and ADRB2 in
the ligand binding region. Interestingly, an antagonistic effect on b-
adrenergic signaling was reported in the early 809s for several
thyronamines. T3AM, 3,5-T2AM, and T0AM interfere with ligand
binding to adrenergic receptors expressed at the plasma membrane
of turkey erythrocytes and inhibited the activation of cAMP
synthesis [83,84]. Of special note, octopamine acts as an orthosteric
ligand for ADRB1 and is an ADRB2-antagonist. These findings are
also interesting under aspects of ligand development for TAAR
[3,60,78,85,86,87,88,89,90], which has to be carefully explored
concerning their potential interactions to other aminergic receptors.
Materials and Methods
Cloning of hTAAR1 and b-adrenergic receptors
Full length human TAAR1 (hTAAR1, NM_138327.1) was
subcloned into the eukaryotic expression vector pcDps, N-
terminally tagged with an hemagglutinin (59 YPYDVPDYA 39)
epitope via KpnI and SpeI restriction sites. For better cell surface
expression hTAAR1 was additionally N-terminally fused with the
first 20 amino acids of the bovine Rhodopsin [18,33]. The human
b1-adrenergic receptor (hADRB1, NM_000684.2)-pcDps con-
struct cloned via KpnI/SpeI containing N-terminal (HA)-tag and C-
terminal Flag-tag (59 DYKDDDDK 39).
Human b2-adrenergic receptor (ADRB2, NM_000024.5) was
subcloned via EcoRI and SpeI with an N-terminal (HA)-tag as well.
All constructs in the eukaryotic expression vector (pcDps) were
Figure 4. Defining the ligand binding region of aminergic receptors. A) The pocket-like ligand binding region (inner crevice surface) of the
human b2-adrenergic receptor (pdb entry code 2RH1) is surrounded by amino acids (lilac sticks, labeled) which are also known from mutagenesis
studies to be important for ligand binding and signal transduction. B) The inverse agonist carazolol is embedded tightly in this pocket of the b2-
adrenergic receptor (top-view) and interacts with residues of TMH 3, 5, and 7 by hydrogen bonds [62]. Differences in binding and effects on receptor
conformation compared to agonists were found to be relatively small, mainly manifested in the interaction pattern to TMH5 or induced side chain
rotamer conformations at TMH5 (amino acids at positions 5.41, 5.42 and 5.46) [80]. C) The crystal structure of dopamine-3 receptor (pdb entry code
3PBL) with the antagonist eticlopride [65] shows a similar localization between the transmembrane helices compared to carazolol in the adrenergic
receptor (B). An aspartate (red stick) at position 3.32 in helix 3 is well known to function as an anchor point for binding of ligands at aminergic
receptors.
doi:10.1371/journal.pone.0027073.g004
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(Perkin-Elmer, Weiterstadt, Germany) and an automatic sequenc-
er (ABI 3710xl; Applied Biosystems, Foster City, CA).
Cell culture, cAMP assay and ligand induced effects
Human embryonic kidney cells (HEK293) were cultured in
Minimum Essential Medium (MEM) Earle’s (Biochrom AG)
supplemented with 10% FBS (PAA Laboratories GmbH),
100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom
AG) and 2 mM L-glutamine (Invitrogen) at 37uC with 5% CO2.
48 well plates were coated with Poly-L-Lysine (Biochrom) and
HEK293 cells were seeded with 37,500 cells per well. Transient
transfection in triplicates with 84 ng DNA/well using metafectene
according to manufactures instructions (Biontex, Munich, Ger-
many) was performed 28 hours later. 40 hours after transfection
cells were pre-incubated for 5 minutes with stimulation buffer
containing of MEM Earle’s media and 1 mM 3-isobutyl-1-
methylxanthine (IBMX, Sigma). This stimulation buffer was used
for all further steps. For ligand competition experiments cells were
incubated with tyramine, 2-phenylethylamine or (6) octopamine
ranging from 6.7 nM to 6700 nM, diluted in stimulation buffer for
15 minutes followed by a stimulation with (-) isoprenaline in
concentrations ranging from 1 nM to 10000 nM for 30 minutes.
Ligands were all purchased from Sigma, Munich. Controls were
incubated with tyramine, b-phenylethylamine, octopamine or
isoprenaline for 45 minutes. All reactions were performed at 37uC
with 5% CO2 saturated air and stopped by aspirating medium.
Cells were lysed at 4uC for 2 h on a shaking platform with cell lysis
buffer containing 5 nM HEPES, 0.1% BSA, 0.3% Tween20 and
1 mM IBMX.
The competitive cyclic adenosine-monophosphate (cAMP) assay
via Alphascreen (Perkin Elmer Life Science, Inc., Boston, MA) was
carried out according to the manufacturers’ protocol. Briefly, 5 ml
of each sample were transferred to a 384 well plate. Acceptor
beads were diluted in 1X HBSS with 1M HEPES, 0.1% BSA,
pH 7.4 and incubated for 30 minutes at room temperature. Then
donor beads and 50 mM biotinylated cAMP diluted in the same
way were added and incubated for an hour at room temperature.
Measurement of the plate was performed using Berthold
Microplate Reader (Berthold Technologies GmbH & Co. KG).
Results are expressed in fold over mock (unstimulated empty
vector). Dose response curves and bar graphs with mean 6 SEM
as well as statistical analysis (paired one-tailed t-test) were
generated using GraphPad Prism Version 4.03.
Structural homology models of hTAARs
Crystal structures of inactive receptor conformations serving for
GPCR homology modeling have been published for several family
A GPCR members like rhodopsin, adenosine- or b-adrenergic
receptors (reviewed in [67]). For modeling of the human TAARs
1, 2, 5, 6, 8, and 9 we used the inactive structural conformation of
the b-2 adrenergic receptor (pdb entry 2RH1, [62]), based on high
sequence similarity between hTAAR1 and b-adrenergic receptor 2
(39% similarity, Blosum62 matrix).
Figure 5. Amino acids covering the ligand binding region of b-adrenergic receptors and TAARs. Amino acids covering the ligand binding
regions of b-adrenergic receptors 1 and 2 are compared with corresponding residues of human TAAR subtypes, dopamine-3 receptor and
invertebrate tyramine (Apis) (TAR) or octopamine receptor (Bombyx) (OAR) (see also amino acid sequence alignment figure S2). This comparison
reveals potential overlapping binding determinants which are predestinated to interact with shared ligands. The amino acids of ADRB1 and ADRB2
ligand binding region are identified by analyzing solved crystal structures complexed with different ligands (figure 4). Residues which are directly
involved in ligand binding at adrenergic receptors are marked by a star-symbol (*). The numbering is provided by the Ballesteros and Weinstein
numbering scheme [66] and consecutively to the entire amino acid sequence. Especially TAAR1 shows similar or even identical side chains (bold) with
the adrenergic receptors, dopamine-3 receptor and OAR or TAR. Highly conserved amino acids between all receptors are marked by a gray
background. Conserved residues within hTAAR subtypes are in italic with a partial gray background. These five residues are located at TMH 2, 3, 6 and
7 and likely encode TAAR specificities compared to other aminergic receptors.
doi:10.1371/journal.pone.0027073.g005
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figure S2) for assignment of corresponding amino acid positions
was made by usage of the Hidden-Markov algorithm derived for
several GPCRs in comparison to the available GPCRs structures
[67]. Refinements of the loop regions were made manually.
The software package Sybyl 7.3.5 (Tripos Inc., St. Louis,
Missouri, 63144, USA) was used for structural modeling
approaches. Gaps of missing residues in the loops of the template
structure were closed by the ‘Loop Search’ tool in Sybyl.
Substituted side chains and loops of each homology model were
subjected to conjugate gradient minimizations until converging at
a termination gradient of 0.05 kcal/(mol*A ˚)) and molecular
dynamics simulation (4 ns) by fixing the backbone of the
transmembrane helices. The AMBER 7.0 force field was used.
Finally, the models were minimized without constraints for 2ns
using the AMBER 7.0 force field. Stability of the models was
validated by checking the geometry using PROCHECK.
Structure images were produced using PyMOL Molecular
Graphics System, version 1.3, Schro ¨dinger, LLC. To facilitate
comparison of different GPCRs we used both the amino acid
numbering of the entire TAARs with their signal peptides and the
Ballesteros-Weinstein numbering scheme [66].
Supporting Information
Figure S1 Dose response curves of hTAAR1 agonists.
The trace amines tyramine (TYR), beta-phenylethylamine (PEA)
and octopamine (OA) activate hTAAR1 via Gs/adenylate cyclase
signaling. HEK293 transiently expressing hTAAR1 were stimu-
lated with each trace amine in concentrations ranging 0.1 mM to
10 nM. Shown are dose response curves fold over basal means 6
SEM from n$4 independent experiments of measured cAMP in
triplicates as described in Material and Methods. PEA was the most
potent agonist (p,0.01), followed by TYR (p,0.05) and OA
(p,0.05) for 10 mM each ligand. Data were analyzed using paired
one-tailed t-test tested against basal value of hTAAR1.
(TIF)
Figure S2 Amino acid sequence alignment of hTAAR1
and homologous receptors. The alignment compares amino
acids of ADRB1, ADRB2, human TAAR, invertebrate octopa-
mine (OAR) and tyramine (TAR) receptors and the human
dopamine-3 receptor (DRD3). Particular background colors
indicating conservation among different receptors and reflecting
biophysical properties of the amino acid side chains: black –
proline, blue – positively charged, cyan/green – aromatic and
hydrophobic, green – hydrophobic, red – negatively charged, gray
– hydrophilic, dark-red – cysteines, magenta – histidine. The
putative helix dimensions and loop regions are assigned according
to observable features in the crystal structure of the inactivated b2-
adrenergic receptor (pdb entry code 2RH1). Furthermore, in
homology to the ligand binding regions of b-adrenergic receptors
amino acid positions covering the putative ligand binding region of
TAARs are marked with a plus (+). Highly conserved amino acids
of family A GPCRs are marked by a star-symbol (*).
(TIF)
Figure S3 Differences between amino acids in the
putative ligand binding region of human TAARs 2, 5, 6,
8 and 9 compared with hTAAR1. Amino acids constituting
the ligand binding region (side chains as sticks) of hTAAR1 (green)
are highlighted at the molecular homology model (backbone, top
view). For the hTAAR subtypes 2, 5, 6, 8 and 9 only side chains
are shown which are different compared to TAAR1 residues. This
comparison reveals that most of the differences are located
spatially between TMH3, TMH5 and TMH6 (red translucent
circles). In other words, between the interfaces of TMH 2-3-6-7 a
Figure 6. TAAR1 shows similarity in the ligand binding region compared with b-adrenergic receptors. A) Superimposition of the
hTAAR1 homology model (extracellular top-side view, green backbone) and the hADRB2 crystal structure (lilac sticks hADRB2, backbone not shown)
reveals similarities of residues which are known to be important for ligand binding and signal transduction in adrenergic receptors (figure 4 and
figure 5). These identical amino acids (sticks) should be involved in binding of shared ligands like isoprenaline. Additional side chains of hTAAR1
covering the putative ligand binding region (figure 5) are represented as green lines. Cysteine bridges (yellow) between loops 1 and 2 or loop 2 and
TMH3 are highlighted and labeled. B) The recently published crystal structure of the turkey b1-adrenergic receptor co-crystallized with the agonist
isoprenaline (pdb entry code 2Y03 [80]) shows main key players for intermolecular hydrogen bonding (yellow dotted lines) at aminergic receptors like
side chains at positions D3.32 (TMH3) (red stick); S5.42, S5.46 (TMH5); and N7.39 (TMH7) (lilac sticks). Interestingly, the inner-pocket surface
(translucent) between the extracellular ends of the helices and ECL2 shows an unoccupied volume which might form a second binding site for small
molecules.
doi:10.1371/journal.pone.0027073.g006
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